MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
Company Details
- Employees
- 120
- Founded
- -
- Address
- Hayarkon 42, Yavne,8122745,israel
- Phone
- (972) 779-7141
- in****@****und.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mediwound.com
- Keywords
- Burn Management, Chronic Wound Care, Enzymatic Debridement, Non-Surgical Tissue Repair, Advanced Wound Care, Biologics, Orphan Drugs, FDA-Approved Therapies, Clinical-Stage Biotech.
- HQ
- Yavne
Mediwound Questions
Mediwound's helpline number is (972) 779-7141
Mediwound's website is mediwound.com
Mediwound's LinkedIn profile is https://il.linkedin.com/company/mediwound
Mediwound has
120 employees.
View email and phone details for 120
employees at Mediwound.
Mediwound's industry is
Pharmaceutical Manufacturing
Mediwound's top competitors are
Biolinerx,
Amai Proteins,
Collplant,
Kamada,
Gamida Cell Ltd.,
Evogene,
Protalix Biotherapeutics,
Dexcel Pharma,
Impact Biotech,
Cytoreason.
Mediwound's support email address is info@mediwound.com
Mediwound's categories are Pharmaceutical Manufacturing
Mediwound's founding year is 2001
